Item 7.01. Regulation FD Disclosure

On December 1, 2021, 180 Life Sciences Corp. (the "Company") issued a press release relating to a keynote address presented by Prof. Jagdeep Nanchahal (a consultant to the Company and the Chairman of our Clinical Advisory Board), at the 2021 International Dupuytren Symposium, held on December 1, 2021, including top line data from the Company's phase 2b clinical trial associated with the use of adalimumab as a potential therapeutic target to help treat Dupuytren's disease.

A copy of the press release is furnished hereto as Exhibit 99.1.

A transcript of Prof. Nanchahal's presentation is furnished herewith as Exhibit 99.2.

The information in Item 7.01 of this Form 8-K and Exhibits 99.1, and 99.2, attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of this Report is not intended to constitute a determination by the Company that the information is material or that the dissemination of the information is required by Regulation FD.

The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K and the transcript furnished as Exhibit 99.2, contain forward-looking statements within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, and, as such, may involve known and unknown risks, uncertainties and assumptions. These forward-looking statements relate to the Company's current expectations and are subject to limitations and qualifications set forth in the press release and transcript, and as well as in the Company's other filings with the Securities and Exchange Commission, including, without limitation, that actual events and/or results may differ materially from those projected in such forward-looking statements. These statements also involve known and unknown risks, which may cause the results of the Company, its divisions and concepts to be materially different than those expressed or implied in such statements. Accordingly, readers should not place undue reliance on any forward-looking statements. Forward-looking statements may include comments as to the Company's beliefs and expectations as to future financial performance, events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the Company's control. More information on potential factors that could affect the Company's financial results is included from time to time in the "Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's periodic and current filings with the SEC, including the Form 10-Qs and Form 10-Ks, filed with the SEC and available at www.sec.gov. Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.





Disclaimer

The information contained in the transcript furnished as Exhibit 99.2 is a textual representation of a video recording of the presentation described above, and while efforts are made to provide an accurate transcription, there may be material errors, omissions or inaccuracies in the reporting of the substance of the recording. The Company does not assume any responsibility for any investment or other decisions made based upon the information provided in this transcript. Users are advised to review the video recording and the Company's SEC filings before making any investment or other decisions. An archived recording of the presentation is accessible through the International Dupuytren website at https://dupuytrensymposium.org/scientific-program.

The link to the website above is provided for informational purposes only and we make no representations regarding such website, the information thereon, or any links accessible therefrom, and do not desire to incorporate any of the information on, or accessible through, such website into this report.

Item 9.01. Financial Statements and Exhibits





(d) Exhibits.



Exhibit No.   Description



99.1*           Press Release dated December 1, 2021
99.2*           Transcript of presentation presented by Prof. Jagdeep Nanchahal, at
              the 2021 International Dupuytren Symposium, held on December 1, 2021
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)




 * Furnished herewith.




                                       1

© Edgar Online, source Glimpses